{"entity":{"id":"aryogen-pharmed","kind":"company","name":"AryoGen Pharmed","aka":["AryoGen","AryoGen Pharmed Co.","آریوژن فارمد"],"tldr":"An Iranian company in the CinnaGen group that makes copies of the cancer antibodies trastuzumab, bevacizumab and rituximab for patients in Iran.","summary":"AryoGen Pharmed's own about page, read in Persian from an Internet Archive copy of 17 May 2025, says the company was founded in 1389 in the Iranian calendar (2010 to 2011) to combine pharmacy with biotechnology, and gives its mission as producing biosimilars to maintain and improve people's quality of life, including meeting the medicine needs of patients with hard-to-treat diseases in Iran and localising every stage of production. Its products page (Internet Archive copy of 14 February 2026) lists Zytux (rituximab), AryoTrust (trastuzumab), Stivant (bevacizumab), Arylia and Artenix (denosumab) among others, and places the company in the CinnaGen pharmaceutical group.\n\nIt sponsored the phase 3 trial that found its bevacizumab, tested as BE1040V and registered as Stivant, non-inferior to the originator with FOLFIRI-3 chemotherapy in 126 patients with metastatic colorectal cancer at 22 Iranian sites (NCT03288987), and a post-marketing safety study of AryoTrust in 597 women given it after surgery for HER2-positive breast cancer (NCT06021379). aryogen.com did not answer from here on 4 November 2026.","asOf":"2026-11-04","links":[{"label":"AryoGen Pharmed: overview (Persian; Internet Archive copy of 17 May 2025)","url":"https://web.archive.org/web/20250517191056/https://www.aryogen.com/about/"},{"label":"AryoGen Pharmed: our products (Persian; Internet Archive copy of 14 February 2026)","url":"https://web.archive.org/web/20260214201350/https://www.aryogen.com/%D9%85%D8%AD%D8%B5%D9%88%D9%84%D8%A7%D8%AA-%D9%85%D8%A7/"},{"label":"ClinicalTrials.gov NCT03288987","url":"https://clinicaltrials.gov/study/NCT03288987"},{"label":"ClinicalTrials.gov NCT06021379","url":"https://clinicaltrials.gov/study/NCT06021379"}],"tags":[],"related":[],"cancers":["colorectal","breast-her2-positive"],"sections":[],"technologies":["biosimilar-manufacturing"],"targets":[],"drugs":["trastuzumab","bevacizumab","rituximab"],"companies":["cinnagen"],"institutions":[],"pathways":[],"terms":["biosimilar"],"trials":["nct03288987","nct06021379"],"people":[],"bottlenecks":[],"keyPapers":["paper-be1040v-bevacizumab-biosimilar-clin-ther-2020","paper-aryotrust-trastuzumab-pms-2024"],"journals":[],"dependsOn":[],"notes":[],"hq":"Tehran to Karaj road, km 24","country":"IR","companyType":"biotech","website":"https://www.aryogen.com","investors":[],"funding":[]},"route":"/companies/aryogen-pharmed/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"technology":[{"id":"biosimilar-manufacturing","kind":"technology","name":"Biosimilar manufacturing and comparability","route":"/technologies/biosimilar-manufacturing/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"company":[{"id":"cinnagen","kind":"company","name":"CinnaGen","route":"/companies/cinnagen/"}],"term":[{"id":"biosimilar","kind":"term","name":"Biosimilar","route":"/terms/biosimilar/"}],"trial":[{"id":"nct06021379","kind":"trial","name":"AryoTrust (AryoGen trastuzumab) post-marketing safety study in HER2-positive breast cancer","route":"/trials/nct06021379/"},{"id":"nct03288987","kind":"trial","name":"Stivant (AryoGen bevacizumab) against Avastin in metastatic colorectal cancer","route":"/trials/nct03288987/"}],"paper":[{"id":"paper-be1040v-bevacizumab-biosimilar-clin-ther-2020","kind":"paper","name":"Efficacy and safety of proposed bevacizumab biosimilar BE1040V in patients with metastatic colorectal cancer: a phase III, randomized, double-blind, noninferiority clinical trial","route":"/key-papers/paper-be1040v-bevacizumab-biosimilar-clin-ther-2020/"},{"id":"paper-aryotrust-trastuzumab-pms-2024","kind":"paper","name":"Safety evaluation of the trastuzumab biosimilar in Iranian women with HER2-positive breast cancer undergoing adjuvant chemotherapy: a post-marketing surveillance","route":"/key-papers/paper-aryotrust-trastuzumab-pms-2024/"}],"institution":[{"id":"iran-fda","kind":"institution","name":"Iran Food and Drug Administration (IFDA)","route":"/institutions/iran-fda/"}]}}